International Journal of Academic Health and Medical Research (IJAHMR)   Year: 2021 | Volume: 5 | Issue: 8 | Page No.: 12-17 Prevalence of Antibody Inhibitors among Sudanese patients with Hemophilia Tarig Osman Khalafallah Ahmed, Shama Adam Osman Khair, Ahmed Abdalla Agabeldour, Hiba Awadelkareem Osman Fadl and Assad Ma. Babker Abstract: Hemophilia is an inherited Bleeding coagulopathy in which coagulation factor deficiencies demonstrate-linked inheritance, Factor VIII and factor XI replacement therapy is effective for hemophilia A and B unless a patient develops an alloantibody (inhibitor) against exogenous FVIII and FXI. Which is the most significant treatment complication for them, associated with considerable morbidity and decreased quality of life. The study aimed to study the prevalence of exogenous alloantibody inhibitors against FVIII and FXI amongst patients with hemophilia A and B in Kordofanian states. A descriptive cross-sectional Carried out in the period from October to December 2019. Informed consent was taken from each patient, then the structured questionnaire was filled, and a blood sample was collected to prepare (PPP) which was tested thru APTT afterward, it was screened for inhibitory antibodies. No one reported to has inhibitors of investigated hemophilic patients amongst a total of 30 hemophiliac patients, aged between (94-33) Years, moreover amidst them, 25(83.3%) belong Hemophilia A, while 5(16.7%) with hemophilia B.also,15 (50%) have mild hemophilia, 12(40%)moderate and 3(10%) severe disease.19(63.3%) suffer from joints complication, they aged between (11-20) years.24(80%) of patients with family history. This study concludes that there are no inhibitors developed in those hemophilia patients, although most of them have developed Hemarthrosis. Finally, the establishment of a local specialized center is recommended to supply hemophiliac patients with treatment and knowledge.